Glucagon-Dependent Suppression of mTORC1 is Associated with Upregulation of Hepatic FGF21 mRNA Translation.

Am J Physiol Endocrinol Metab

Department of Cellular and Molecular Physiology, Penn State College of Medicine, 500 University Drive, Hershey PA 17033, United States.

Published: May 2020

Fibroblast growth factor 21 (FGF21) is a peptide hormone that acts to enhance insulin sensitivity and reverse many of the metabolic defects associated with consumption of a high-fat diet. Recent studies show that the liver is the primary source of FGF21 in the blood, and that hepatic FGF21 expression is upregulated by glucagon. Interestingly, glucagon acts to upregulate FGF21 production by primary cultures of rat hepatocytes and H4IIE and HepG2 hepatocarcinoma cells independent of changes in FGF21 mRNA abundance, suggesting that FGF21 protein expression is regulated post-transcriptionally. Based on these observations, the goal of the present study was to assess whether or not FGF21 mRNA is translationally regulated. The results show that FGF21 mRNA translation and secretion of the hormone are significantly upregulated in H4IIE cells exposed to 25 nM glucagon, independent of changes in FGF21 mRNA abundance. Furthermore, the glucagon-induced upregulation of FGF21 mRNA translation is associated with suppressed activity of the mechanistic target of rapamycin in complex 1 (mTORC1). Similarly, the results show that rapamycin-induced suppression of mTORC1 leads to upregulation of FGF21 mRNA translation with no change in FGF21 mRNA abundance. In contrast, activation of mTORC1 by refreshing the culture medium leads to downregulation of FGF21 mRNA translation. Notably, re-feeding fasted rats also leads to downregulation of FGF21 mRNA translation concomitantly with activation of mTORC1 in the liver. Overall, the findings support a model in which glucagon acts to upregulate FGF21 production by hepatocytes through suppression of mTORC1 and subsequent upregulation of FGF21 mRNA translation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468783PMC
http://dx.doi.org/10.1152/ajpendo.00555.2019DOI Listing

Publication Analysis

Top Keywords

fgf21 mrna
44
mrna translation
28
fgf21
17
suppression mtorc1
12
mrna abundance
12
upregulation fgf21
12
mrna
11
hepatic fgf21
8
glucagon acts
8
acts upregulate
8

Similar Publications

Site-specific analysis and functional characterization of N-linked glycosylation for β-Klotho protein.

Int J Biol Macromol

December 2024

State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, 21 Sassoon Road, Pokfulam 999077, Hong Kong, China; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam 999077, Hong Kong, China; Department of Pharmacology and Pharmacy, The University of Hong Kong, 21 Sassoon Road, Pokfulam 999077, Hong Kong, China. Electronic address:

β-Klotho (KLB), a type I transmembrane protein, serves as an obligate co-receptor determining the tissue-specific actions of endocrine fibroblast growth factors (FGFs). Despite accumulative evidence suggesting the occurrence of N-glycosylation in the KLB protein, the precise N-glycosites, glycoforms, and the impacts of N-glycosylation on the expression and function of the KLB protein remain unexplored. Employing a mass spectrometry-based approach, a total of 12 N-glycosites displaying heterogeneous site occupancy and glycoforms were identified within the extracellular region of the recombinant human KLB protein.

View Article and Find Full Text PDF

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is highly prevalent with major risk of progression to Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Hepatocellular Carcinoma (HCC). Recently, osteoporosis and bone fracture have emerged as sexually-dimorphic comorbidities of MASLD yet the mechanisms of this bone loss are unknown. Herein, we address these knowledge gaps using DIAMOND mice which develop MASLD, MASH, and HCC via Western diet exposure.

View Article and Find Full Text PDF

Objectives: Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the expression of target genes.

View Article and Find Full Text PDF

Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction.

Antiviral Res

November 2024

Fundación para El Fomento de La Investigación Sanitaria y Biomédica en La Comunidad Valenciana (FISABIO)-Hospital Universitario Doctor Peset, Valencia, Spain; Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; Departamento de Fisiología, Universitat de València, Valencia, Spain. Electronic address:

Article Synopsis
  • - Recent studies link certain antiretroviral therapies, particularly those with integrase inhibitors like bictegravir (BIC) and tenofovir alafenamide (TAF), to weight gain and metabolic issues, but the reasons behind this are still unclear.
  • - In experiments on mice and liver cells, BIC was shown to significantly disrupt glucose metabolism, leading to higher glucose levels and insulin resistance, while also causing mitochondrial stress.
  • - The research indicates that BIC may worsen insulin resistance and related metabolic disorders in people living with HIV, suggesting a need for further clinical investigations.
View Article and Find Full Text PDF

Hepatocyte-specific GDF15 overexpression improves high-fat diet-induced obesity and hepatic steatosis in mice via hepatic FGF21 induction.

Sci Rep

October 2024

Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyou-ku, Kyoto, 602-8566, Japan.

Article Synopsis
  • GDF15 and FGF21 are liver-secreted cytokines that show potential as treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), but their interaction is not fully understood.
  • Overexpressing GDF15 or FGF21 in mice on a high-fat diet led to reduced body weight, fat mass, and insulin resistance, with GDF15 also lowering weight without affecting food intake.
  • GDF15 may enhance fatty acid metabolism and induce FGF21 expression through specific cellular mechanisms, indicating that their interaction is significant for addressing MASLD.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!